company background image
EUZ

Eckert & Ziegler Strahlen- und MedizintechnikXTRA:EUZ Stock Report

Market Cap

€2.6b

7D

6.6%

1Y

195.3%

Updated

22 Oct, 2021

Data

Company Financials +
EUZ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

EUZ Overview

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide.

Price History & Performance

Summary of all time highs, changes and price drops for Eckert & Ziegler Strahlen- und Medizintechnik
Historical stock prices
Current Share Price€127.50
52 Week High€38.26
52 Week Low€141.40
Beta0.61
1 Month Change-2.89%
3 Month Change17.19%
1 Year Change195.28%
3 Year Change1,008.70%
5 Year Change2,309.07%
Change since IPO1,956.45%

Recent News & Updates

Sep 14
Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Deserve Your Attention Today

Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Deserve Your Attention Today

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Jul 29
Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Have The Makings Of A Multi-Bagger

Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Have The Makings Of A Multi-Bagger

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...

Jun 11
Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Is An Interesting Stock

Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Is An Interesting Stock

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Shareholder Returns

EUZDE Medical EquipmentDE Market
7D6.6%2.2%0.3%
1Y195.3%58.8%24.5%

Return vs Industry: EUZ exceeded the German Medical Equipment industry which returned 56.6% over the past year.

Return vs Market: EUZ exceeded the German Market which returned 24.7% over the past year.

Price Volatility

Is EUZ's price volatile compared to industry and market?
EUZ volatility
EUZ Beta0.61
Industry Beta0.41
Market Beta1

Stable Share Price: EUZ is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: EUZ's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1992814Andreas Eckerthttps://www.ezag.com

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates through two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma.

Eckert & Ziegler Strahlen- und Medizintechnik Fundamentals Summary

How do Eckert & Ziegler Strahlen- und Medizintechnik's earnings and revenue compare to its market cap?
EUZ fundamental statistics
Market Cap€2.61b
Earnings (TTM)€32.46m
Revenue (TTM)€182.02m

81.5x

P/E Ratio

14.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EUZ income statement (TTM)
Revenue€182.02m
Cost of Revenue€88.32m
Gross Profit€93.70m
Expenses€61.24m
Earnings€32.46m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 09, 2021

Earnings per share (EPS)1.56
Gross Margin51.48%
Net Profit Margin17.83%
Debt/Equity Ratio0%

How did EUZ perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

29%

Payout Ratio

Valuation

Is Eckert & Ziegler Strahlen- und Medizintechnik undervalued compared to its fair value and its price relative to the market?

81.5x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: EUZ (€127.5) is trading above our estimate of fair value (€66.17)

Significantly Below Fair Value: EUZ is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: EUZ is poor value based on its PE Ratio (81.5x) compared to the German Medical Equipment industry average (28.1x).

PE vs Market: EUZ is poor value based on its PE Ratio (81.5x) compared to the German market (22.8x).


Price to Earnings Growth Ratio

PEG Ratio: EUZ is poor value based on its PEG Ratio (3x)


Price to Book Ratio

PB vs Industry: EUZ is overvalued based on its PB Ratio (15.4x) compared to the DE Medical Equipment industry average (4.3x).


Future Growth

How is Eckert & Ziegler Strahlen- und Medizintechnik forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

26.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EUZ's forecast earnings growth (26.7% per year) is above the savings rate (-0.01%).

Earnings vs Market: EUZ's earnings (26.7% per year) are forecast to grow faster than the German market (12.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: EUZ's revenue (19.3% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: EUZ's revenue (19.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EUZ's Return on Equity is forecast to be high in 3 years time (21.9%)


Past Performance

How has Eckert & Ziegler Strahlen- und Medizintechnik performed over the past 5 years?

24.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EUZ has high quality earnings.

Growing Profit Margin: EUZ's current net profit margins (17.8%) are higher than last year (12.5%).


Past Earnings Growth Analysis

Earnings Trend: EUZ's earnings have grown significantly by 24.3% per year over the past 5 years.

Accelerating Growth: EUZ's earnings growth over the past year (50.1%) exceeds its 5-year average (24.3% per year).

Earnings vs Industry: EUZ earnings growth over the past year (50.1%) underperformed the Medical Equipment industry 92.9%.


Return on Equity

High ROE: EUZ's Return on Equity (18.4%) is considered low.


Financial Health

How is Eckert & Ziegler Strahlen- und Medizintechnik's financial position?


Financial Position Analysis

Short Term Liabilities: EUZ's short term assets (€166.8M) exceed its short term liabilities (€46.4M).

Long Term Liabilities: EUZ's short term assets (€166.8M) exceed its long term liabilities (€97.7M).


Debt to Equity History and Analysis

Debt Level: EUZ is debt free.

Reducing Debt: EUZ has no debt compared to 5 years ago when its debt to equity ratio was 13.2%.

Debt Coverage: EUZ has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: EUZ has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Eckert & Ziegler Strahlen- und Medizintechnik current dividend yield, its reliability and sustainability?

0.35%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: EUZ's dividend (0.35%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1%).

High Dividend: EUZ's dividend (0.35%) is low compared to the top 25% of dividend payers in the German market (3.24%).


Stability and Growth of Payments

Stable Dividend: EUZ is not paying a notable dividend for the German market, therefore no need to check if payments are stable.

Growing Dividend: EUZ is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: EUZ is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EUZ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Andreas Eckert (61 yo)

no data

Tenure

€978,027

Compensation

Dr. Andreas Eckert, PhD, is the Founder and Managing Partner of ELSA Eckert Life Science Accelerator GmbH. Dr. Exkert is the Founder of Eckert & Ziegler Strahlen & Medizintechnik AG and serves as its Chief...


CEO Compensation Analysis

Compensation vs Market: Andreas's total compensation ($USD1.14M) is below average for companies of similar size in the German market ($USD1.88M).

Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: EUZ's management team is seasoned and experienced (6.3 years average tenure).


Board Members

Experienced Board: EUZ's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Eckert & Ziegler Strahlen- und Medizintechnik AG's employee growth, exchange listings and data sources


Key Information

  • Name: Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Ticker: EUZ
  • Exchange: XTRA
  • Founded: 1992
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €2.610b
  • Shares outstanding: 20.75m
  • Website: https://www.ezag.com

Number of Employees


Location

  • Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Robert-Rössle-Strasse 10
  • Berlin
  • Berlin
  • 13125
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/22 20:52
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.